Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of GSK548470 administered
once daily at a dose level of 300 mg to Japanese patients with compensated chronic hepatitis
B untreated with any nucleic acid analogue. In efficacy, the non-inferiority of GSK548470 to
ETV will be verified using the antiviral effect as the index.